Nicotinic Acetylcholine Receptors in the Mesolimbic Pathway
Total Page:16
File Type:pdf, Size:1020Kb
The Journal of Neuroscience, April 14, 2010 • 30(15):5311–5325 • 5311 Behavioral/Systems/Cognitive Nicotinic Acetylcholine Receptors in the Mesolimbic Pathway: Primary Role of Ventral Tegmental Area ␣62* Receptors in Mediating Systemic Nicotine Effects on Dopamine Release, Locomotion, and Reinforcement Cecilia Gotti,1* Stefania Guiducci,2* Vincenzo Tedesco,4 Silvia Corbioli,5 Lara Zanetti,2 Milena Moretti,1 Alessio Zanardi,2 Roberto Rimondini,7 Manolo Mugnaini,6 Francesco Clementi,1 Christian Chiamulera,4 and Michele Zoli2,3 1Consiglio Nazionale delle Ricerche, Institute of Neuroscience, Cellular and Molecular Pharmacology Center, Department of Medical Pharmacology, University of Milan, 20129 Milan, Italy, 2Department of Biomedical Sciences, Section of Physiology, University of Modena and Reggio Emilia, and 3Centro AntiFumo (Interdipartimentale), Azienda Ospedaliero–Universitaria Policlinico di Modena, 41100 Modena, Italy, 4Neuropsychopharmacology Laboratory, Section of Pharmacology, Department of Medicine and Public Health, University of Verona, 37134 Verona, Italy, 5Preclinical Drug Discovery and Enabling Technologies and 6Addiction and Sleep Disorders Discovery Performance Unit, Neurosciences Center of Excellence for Drug Discovery, GlaxoSmithKline Medicines Research Center, 37135 Verona, Italy, and 7Department of Pharmacology, University of Bologna, 40126 Bologna, Italy ␣6* nicotinic acetylcholine receptors (nAChRs) are highly and selectively expressed by mesostriatal dopamine (DA) neurons. These neurons are thought to mediate several behavioral effects of nicotine, including locomotion, habit learning, and reinforcement. Yet the functional role of ␣6* nAChRs in midbrain DA neurons is mostly unknown. The aim of this study was to determine the composition and in vivo functional role of ␣6* nAChR in mesolimbic DA neurons of male rats. Immunoprecipitation and immunopurification techniques coupled with cell-specific lesions showed that the composition of ␣6* nAChR in the mesostriatal system is heterogeneous, with (non- ␣4)␣62* being predominant in the mesolimbic pathway and ␣4␣62* in the nigrostriatal pathway. We verified whether ␣6* receptors mediate the systemic effects of nicotine on the mesolimbic DA pathway by perfusing the selective antagonists ␣-conotoxin MII (CntxMII) (␣3/␣62* selective) or ␣-conotoxin PIA (CntxPIA) (␣62* selective) into ventral tegmental area (VTA). The intra-VTA perfusion of CntxMII or CntxPIA markedly decreased systemic nicotine-elicited DA release in the nucleus accumbens and habituated locomotion; the intra-VTA perfusion of CntxMII also decreased the rate of nicotine infusion in the maintenance phase of nicotine, but not of food, self-administration. Overall, the results of these experiments show that the ␣62* nAChRs expressed in the VTA are necessary for the effects of systemic nicotine on DA neuron activity and DA-dependent behaviors such as locomotion and reinforcement, and suggest that ␣62*-selective compounds capable of crossing the blood–brain barrier may affect the addictive properties of nicotine and therefore be useful in the treatment of tobacco dependence. Introduction the nucleus accumbens (nAc) and tuberculum olfactorium] and The mesostriatal dopamine (DA) pathway is a major brain target dorsal [the nigrostriatal DA pathway, comprising cell bodies in of nicotine. Its ventral [the mesolimbic DA pathway, comprising the substantia nigra and terminals in the caudate–putamen cell bodies in the ventral tegmental area (VTA) and terminals in (CPu)] components both express high levels of nicotinic acetyl- choline receptors (nAChRs). These receptors are thought to me- diate several main behavioral effects of nicotine, including the Received Oct. 13, 2009; revised March 2, 2010; accepted March 8, 2010. This work was supported by Italian Project of Main National Interest (PRIN) Grant 20072BTSR2 (F.C., M.Z.); regulation of locomotor activity and reinforcement in the me- European Community Grant Neurocypres (C.G., M.Z.); a grant from the Neurosciences Center of Excellence for Drug solimbic component and habit learning in the nigrostriatal com- Discovery, GlaxoSmithKline (Verona, Italy) (M.Z.); Fondazione Cariplo Grant 2006/0882/104878 and a grant from ponent (Di Chiara, 2000; Janhunen and Ahtee, 2007). Associazione Oasi Maria Santissima (Troina, Italy) (F.C.); and Fondazione Cariplo Grant 2006/0779/109251 and Neuronal nAChRs comprise a heterogeneous family of pen- Compagnia San Paolo Grant 2005-1964 (C.G.). We thank the technical assistance of Dr. Claudia Tregnago, Marzia Di Chio, Dr. Chiara Giuliano, Dr. Alessia Auber, Dr. Luca Zangrandi, Alberto Ruffo, and Federica Vinco. We thank Dr. tameric oligomers made up of combinations of subunits encoded Stefano Fontana and Dr. Mario Corsi for careful reading of this manuscript. by at least 11 different genes in mammals. They have been The authors declare no competing financial interests. grouped into two subfamilies based on their phylogenetic, func- *C.G. and S.G. contributed equally to this work. tional, and pharmacological properties (Le Nove`re and Chan- Correspondence should be addressed to Michele Zoli, Department of Biomedical Sciences, Section of Physiology, geux, 1995; Corringer et al., 2000; Gotti et al., 2006), namely the University of Modena and Reggio Emilia, via Campi 287, 41100 Modena, Italy. E-mail: [email protected]. ␣ ␣ ␣ ␣ DOI:10.1523/JNEUROSCI.5095-09.2010 -bungarotoxin (Bgtx)-sensitive nAChRs ( 7, 9, and 10 sub- Copyright © 2010 the authors 0270-6474/10/305311-15$15.00/0 units) and the Bgtx-insensitive nAChRs (␣2–␣6 and 2–4 sub- 5312 • J. Neurosci., April 14, 2010 • 30(15):5311–5325 Gotti et al. • ␣62* nAChRs in Mesolimbic Dopamine Pathway units). These latter subunits can combine to form a number of affinity purified. The peptides obtained from mouse, rat, or human se- functionally and pharmacologically different heteropentamers quences were located in the putative cytoplasmic (CYT) loop between consisting of two to four different subunits. M3 and M4 and/or at the C terminal. For almost all of the subunits, we Most nAChR subunits are expressed in midbrain DA neurons raised antisera directed against two separate peptides of the same subunit (Le Nove`re et al., 1996; Charpantier et al., 1998; Azam et al., and the immunoprecipitation values reported are the mean of results obtained using both antisera. For a full characterization of nAChR- 2002). Two main populations of Bgtx-insensitive nAChRs are subunit antibodies, see Grady et al. (2009), their supplemental Table 1. expressed by DA cell body/dendrite compartment of the ventral ␣ ␣  ␣  The affinity-purified antisera were bound to CNBr-activated Sepharose midbrain, 4(non- 6) 2* and 6 2* nAChRs (Klink et al., at a concentration of 1 mg/ml, and the columns used for subtype 2001; Champtiaux et al., 2003). However, their complete subunit immunopurification. composition and possible cellular or subcellular heterogeneity Characterization of antibody specificity was performed using nAChR are not known. Much more is known on the composition of subunit knock-out mice, brain region extracts and cells transfected with nAChRs expressed by striatal DA terminals. Converging immu- subunit cDNAs as described previously (Zoli et al., 2002; Champtiaux et nochemical and neurochemical evidence (Grady et al., 2007) al., 2003; Moretti et al., 2004; Gotti et al., 2005a). demonstrate the presence of four main populations: ␣42, 6-Hydroxydopamine and N-2-chlorethyl-N-ethyl-2-bromobenzylamine ␣4␣52, ␣62(3), and ␣4␣62(3) nAChRs. Less is known on lesions and eye enucleation. Unilateral denervation of mesostriatal DA pathways was performed by injecting the selective neurotoxin 6-hydro- their regional and cellular heterogeneity. Yet a recent paper ␣  xydopamine (6OHDA) (10 g/4 l) in the medial forebrain bundle [co- showed that 6 2 responses dominate in the nAc but not in the ordinates from bregma: anterior (A), Ϫ4 mm; lateral (L), 1.8 mm; deep CPu (Exley et al., 2008). (D), Ϫ7.5 mm] (Paxinos and Watson, 2007). [ 3H]WIN 35,428 binding ␣  Much evidence has been collected on the functions of 6 2* was determined individually in dorsal and ventral striata and ventral nAChRs in in vitro and ex vivo preparations (Champtiaux et al., midbrain from unlesioned and 6OHDA-lesioned rats using a saturat- 3 2003; Salminen et al., 2004; Grady et al., 2007; Drenan et al., ing concentration of 100 nM [ H]WIN 35,428 in the presence or 2008). In addition, some recent papers have started to elucidate absence of 10 M GBR 12935 [1-(2-(diphenylmethoxy)ethyl)-4-(3- the functional role of ␣6* nAChRs in vivo, showing their involve- phenylpropyl)piperazine]. 6OHDA-lesioned tissues with a decrease 3 ment in nicotine-elicited locomotion (Drenan et al., 2008) and of [ H]WIN 35,428 Ͻ80% were discarded. nicotine self-administration (Pons et al., 2008; Brunzell et al., Noradrenaline (NA) denervation was obtained by injection of the se- 2010). lective toxin N-2-chlorethyl-N-ethyl-2-bromobenzylamine (DSP-4) (50 mg/kg, i.p.; Sigma-Aldrich). The animals were killed 14 d after the toxin The purpose of the present experiments is to assess the role of ␣  injection, and the dorsal and ventral striatum as well as ventral midbrain 6 2* nAChRs of the mesolimbic DA pathway in mediating in were dissected and rapidly frozen. Binding of [N-methyl- 3H]nisoxetine, vivo neurochemical and behavioral effects of systemic nicotine. a selective ligand for noradrenaline transporter, was used to assess the With this aim, we identified